Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The OTCBB Garbage Dump -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (2112)	9/13/1999 12:12:00 PM
From: JamesB	Read Replies (1) \| Respond to of 2942

IMDS, news looks good, got some, though not THAT much ;-)

To: Wayne Rumball who wrote (2112)	9/13/1999 12:13:00 PM
From: LANCE B	Respond to of 2942

IMDS - HOPE THEY ARE NOT AT LUNCH FOR THIS NEWS; PR NEWSWIRE) Imaging Diagnostic Systems Receives Patent for Laser Imaging Imaging Diagnostic Systems Receives Patent for Laser Imaging Apparatus Using 'Biomedical Markers' That Bind to Cancer Cells FORT LAUDERDALE, Fla., Sept. 13 /PRNewswire/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) announced today that their patent application for the laser imaging apparatus using biomedical markers that bind to cancer cells has received issue notification from the United States Department of Commerce, Patent and Trademark office. The patent will be issued September 14, 1999, as Patent No. 5,952,664. A "fluorescent marker" is a chemical compound that allows light to be absorbed at specific locations to locate cancerous tissues. The fluorescent marker is designed to have a high specificity for cancer cells. When exposed to light at a specific wavelength, the fluorescent marker will "glow" at a unique wavelength allowing it to be easily differentiated from normal tissue. The fluorescence CTLM(TM) scanner will use this effect to localize the cancerous tissue. "Fluorescence Markers" is a compound that the Company is currently studying in conjunction with major pharmaceutical companies as an advanced diagnostic feature to be used with the Company's laser mammography system: The CTLM(TM) in combination with the fluorescent feature has the potential to be used with photodynamic therapy (PDT) to aid in the treatment of breast cancer. Imaging Diagnostics' CTLM(TM) is currently in the second series of the investigational clinical trials at Nassau County Medical Center. This study involves 275 patients as part of the data required for the submission to the FDA for marketing approval. This release may contain forward-looking statements with the meanings of Section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. Actual results and events could differ materially from those projected as a result of the "known uncertainties" set forth in detail in the Company's filings with the Securities and Exchange Commission. SOURCE Imaging Diagnostic Systems, Inc. -0- 09/13/1999 /CONTACT: Deborah O'Brien of Imaging Diagnostic Systems, Inc., 954-581-9800/ /Web site: imds.com (IMDS) CO: Imaging Diagnostic Systems, Inc. ST: Florida IN: MTC SU: * end of story *